Jun 15, 2020 | Controlled Release, Drug Bioavailability, Main Blog, Peptide |
Enhancing Drug Bioavailability and Solubility Approximately 40% of drugs on the market place and a high percentage of APIs in development are poorly soluble. Optimization of drug solubility and BA of therapeutics stands as one of the top challenges faced by the...
Jun 8, 2020 | Controlled Release, Drug Bioavailability, Main Blog, Peptide |
Extended Duration Parenteral Products as Patient Adherence Strategies For a number of years, extended-release parenteral formulations have garnered enormous attention due to their effective drug concentrations over extended periods and improve patient compliance...
May 26, 2020 | Controlled Release, Drug Bioavailability, Main Blog, Peptide |
Improving Adherence with Patient-Centric Formulations The term “patient centered,” “patient centric,” or “patient centricity” has increasingly grown in use in the scientific community in a wide variety of contexts. Generally, patient centric medicines are recognized...
Apr 15, 2020 | Controlled Release, Drug Bioavailability, Main Blog, Peptide |
Controlled delivery formulations remain one of the favored tools for advancing the lifecycle of pharmaceutical products, and excipient selection is vitally important. A traditional strategy is to initially launch multiple daily doses of an immediate-release (IR)...
Sep 13, 2019 | Controlled Release, Drug Bioavailability, Main Blog, Peptide |
Beyond 2020, the global Peptide Therapeutics market is expected to eclipse $42 billion. This dramatic market increase is driven by both growing incidences of cardiovascular and metabolic diseases, and technological enhancements in peptide synthesis that include...
Recent Comments